We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CRWD:NASDAQCrowdStrike Holdings, Inc. Analysis

Data as of 2026-03-09 - not real-time

$434.13

Latest Price

8/10Risk

Risk Level: High

Executive Summary

CrowdStrike posted a robust fourth‑quarter revenue of $1.31 billion, beating estimates, and reported a 47% year‑over‑year jump in net‑new annual recurring revenue, fueling a post‑earnings rally of roughly 10% and an HSBC upgrade to Buy. The company’s revenue growth remains strong at 23% YoY with an impressive 74.8% gross margin, though operating profitability is still thin (1% operating margin) and net profit remains negative. Valuation metrics are stretched: the forward P/E sits near 70× and the price‑to‑book is above 24×, while a discounted cash‑flow model suggests a fair value of about $245, implying the stock trades at a ~13% premium to intrinsic estimates.
Technical indicators show the price (≈$434) sitting below the 20‑, 50‑ and 200‑day SMAs, a bearish trend direction, but a bullish MACD histogram and RSI near 57 suggest limited downside momentum. Volatility is high (≈66% 30‑day) and beta exceeds 1.4, indicating sensitivity to market swings, yet volume is increasing and support around $343 provides a cushion. The combination of strong top‑line growth, elevated valuation, and heightened risk points to a cautious but opportunistic stance.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Post‑earnings price rally and upgraded outlook
  • Support level near $343 limiting downside
  • Increasing trading volume indicating market interest

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Sustained revenue growth and expanding ARR base
  • Strong cash generation (free cash flow > $1.6 billion)
  • Strategic AI‑driven security offerings enhancing competitive moat

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Valuation remains significantly above DCF fair value
  • Profitability has not yet turned positive despite margin expansion
  • High volatility and beta suggest continued price swings

Key Metrics & Analysis

Financial Health

Revenue Growth23.30%
Profit Margin-3.38%
P/E Ratio70.3
ROE-4.14%
ROA-1.57%
Debt/Equity18.34
P/B Ratio24.8
Op. Cash Flow$1.6B
Free Cash Flow$1.6B
Industry P/E36.8

Technical Analysis

TrendBearish
RSI57.4
Support$342.72
Resistance$438.28
MA 20$400.47
MA 50$432.36
MA 200$468.95
MACDBullish
VolumeIncreasing
Fear & Greed Index75.89

Valuation

Fair Value$244.52
Target Price$493.85
Upside/Downside13.76%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta1.48
Volatility65.79%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.